Phaseline

Companies › Daewon Pharmaceutical

Daewon Pharmaceutical: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Immunology, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DW1807–Phase 3Perennial Allergic Rhinitis Accompanied by Asthma–
DW1807-R2–Phase 3Perennial Allergic Rhinitis Accompanied by Asthma–
DW4421–Phase 1Healthy Adult–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07343245DW4421Phase 1Healthy AdultOtherFeb 2026
NCT07168473DW1807Phase 3Perennial Allergic Rhinitis Accompanied by AsthmaImmunologyAug 2026
NCT07168473DW1807-R2Phase 3Perennial Allergic Rhinitis Accompanied by AsthmaImmunologyAug 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Astria Therapeutics Accro Bioscience (Suzhou) Prime Gene Therapeutics Zhejiang Sunshine Mandi Pharmaceutical Paradigm Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.